Separate terms with OR to return results that match either term.
 
Clear All

700 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
HCPCS (Ascending) Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C9148 Teclistamab-cqyv Tecvayli 0.5mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2022 March 17, 2023 July 11, 2023 No Longer Used
C9155 Epcoritamab-bysp Epkinly 0.16mg Immunotherapy Monoclonal Antibody CD20, CD3 No 2023 Aug. 28, 2023 Dec. 7, 2023 No Longer Used
C9163 Talquetamab Talvey 0.25mg Immunotherapy T Cell Receptor (TCR) GPRC5D, CD3 No 2023 Dec. 7, 2023 In Use
C9165 Elranatamab-bcmm Elrexfio 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2023 Dec. 7, 2023 In Use
C9205 Oxaliplatin Eloxatin unspecified Chemotherapy Alkylating Agent Platinum Compound No 2002 July 1, 2003 Dec. 31, 2005 No Longer Used
C9210 Palonosetron Aloxi 25 mcg Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist No 2003 Jan. 1, 2004 Dec. 31, 2004 No Longer Used
C9213 Pemetrexed Alimta 10 mg Chemotherapy Antimetabolite Folic Acid Analog No 2004 Feb. 4, 2004 Dec. 31, 2004 No Longer Used
C9214 Bevacizumab Avastin 10 mg Immunotherapy Monoclonal Antibody VEGFR No 2004 Feb. 26, 2004 Dec. 31, 2004 No Longer Used
C9215 Cetuximab Erbitux 10 mg Immunotherapy Monoclonal Antibody EGFR No 2004 Feb. 12, 2004 Dec. 31, 2004 No Longer Used
C9216 Abarelix Plenaxis 10 mg Hormonal Therapy Androgen Receptor Inhibitor LHRH antagonist No 2003 2005 Jan. 1, 2005 No Longer Used

Found 700 results in 2 millisecondsExport these results

The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.